Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
Is a |
Fluticasone propionate |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Fluticasone propionate (substance) |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Adrenal hormone |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Corticosterone |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Bronchodilator (substance) |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
Is a |
Product containing fluticasone and salmeterol (medicinal product) |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Salmeterol xinafoate |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Adrenal hormone agent |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Fluticasone (substance) |
false |
Inferred relationship |
Some |
|
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Salmeterol (substance) |
false |
Inferred relationship |
Some |
|
|